Sanofi's Nexviazyme Achieves Positive Phase 3 Results for Infantile-Onset Pompe Disease
SNY is trading near its 52-week low of $40.89 (5.6% above the low).
Summary
Sanofi's Nexviazyme demonstrated positive Phase 3 results for infantile-onset Pompe disease, paving the way for a US regulatory submission to expand its label.
Key Events · Product Development and Regulatory · SNY
-
Positive Phase 3 Results
Sanofi's Nexviazyme met all primary and secondary endpoints in the Baby-COMET Phase 3 study for infantile-onset Pompe disease (IOPD) in treatment-naïve infants.
-
Regulatory Submission Planned
Sanofi intends to submit the positive Phase 3 data to the FDA in the second half of 2026 to support a label extension for Nexviazyme in IOPD in the US.
-
Safety Profile Confirmed
The drug was well tolerated in the study, with a safety profile consistent with established avalglucosidase alfa, and no serious treatment-related adverse events, deaths, or discontinuations.
Analysis · SNY · Life Sciences
Sanofi announced successful Phase 3 results for Nexviazyme in infantile-onset Pompe disease (IOPD), meeting all primary and secondary endpoints. This data will support a regulatory submission for a label expansion in the US, broadening the drug's market and addressing a severe, rapidly progressive condition in infants.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNY was trading at $43.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.8B. The 52-week trading range was $40.89 to $52.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.